Hybio Pharmaceutical and KuCoin Join Forces to Pioneer China’s First RWA Pilot in Innovative Drug Development
On August 4, 2025, Hybio Pharmaceutical and KuCoin, a world-leading digital asset platform, formally signed a strategic cooperation letter of intent. Both parties plan to jointly explore and advance the first RWA (Real World Asset) tokenization pilot project in Hong Kong with "future income rights from innovative drug R&D" as the underlying asset, originating from the Chinese mainland.
This collaboration centers on Hybio Pharmaceutical's independently developed innovative and generic drug pipelines with high technological barriers, exploring a compliant RWA (Real World Asset) issuance pathway that aligns with the virtual asset regulatory frameworks of both the Chinese mainland and Hong Kong. It aims to introduce a replicable new mechanism for financing and value discovery in the biopharmaceutical sector.
Under the agreement, Hybio Pharmaceutical will contribute its technological accumulation and R&D pipeline in the field of GLP-1 peptide blockbuster drugs as the underlying assets. KuCoin, leveraging its strengths in blockchain technology, end-to-end RWA solutions, and global compliance resources, will provide integrated support for the project, including on-chain mapping, asset tokenization, transaction matching, and revenue distribution.
The strategic synergy between the two parties is mainly reflected in three aspects:
Capital Synergy: Leveraging KuCoin's global network of over 41 million users to expand overseas compliant capital channels for Hybio Pharmaceutical.
Technical Synergy: Enabling transparent mapping of key R&D milestones and on-chain revenue data to enhance investor trust.
Brand Synergy: Establishing an international image of "Chinese Innovation, Global Standards" and jointly exploring a model project for RWA compliance in China's pharmaceutical industry.
Hybio Pharmaceutical stated, "Through this collaboration, we aim to create an innovative pathway integrating technology, pharmaceuticals, and finance, on the premise of ensuring data security and legal compliance. This will help advance the release of the value of R&D assets and stimulate global capital's attention and participation in China's original innovative drugs."
KuCoin commented, "Hybio Pharmaceutical represents the hard technological strength in China's biopharmaceutical sector. We hope to take this project as a starting point to explore more RWA practices for high-quality assets and facilitate industrial transformation and upgrading."
This collaboration not only marks a key step for Hybio Pharmaceutical in its global layout but also is expected to provide a new paradigm and inspiration for the entire pharmaceutical industry in the integration of capital and technology.
About Hybio Pharmaceutical
A national high-tech enterprise listed on China's A-share market, specializing in the R&D, production, and sales of innovative drugs. With over 20 years of dedication to peptide drugs, it boasts a complete formulation pipeline covering mainstream global peptide targets, including but not limited to original innovative drugs of GLP-1R/GIPR/GCGR triple Receptor Agonists, as well as global blockbuster peptide ANDA formulations such as Retatrutide, Tirzepatide, Semaglutide, and Liraglutide. It has accumulated nearly 500 authorized patents domestically and internationally. It is the world's first company to obtain FDA approval for the ANDA of GLP-1 daily formulation Liraglutide, with products entering regulated markets in Europe and the United States.
About KuCoin
Founded in 2017, KuCoin is a pioneering and widely recognized platform in the global digital economy development. It has built a solid foundation based on cutting-edge blockchain infrastructure, liquidity solutions, and excellent user experience, providing comprehensive digital asset solutions for global users. It currently serves 41 million users across more than 200 countries and regions worldwide and was named Forbes' 2025 Best Cryptocurrency Exchange. The platform has technical reserves for end-to-end RWA issuance, including asset verification, revenue dataization, asset on-chain, transaction security, institutional-grade custody, on-chain revenue distribution, liquidity provision, and trading platform services. It is committed to making every effort to obtain all licenses required by Hong Kong regulatory authorities.